GeneDx, Inc. is a global leader in genomics, providing advanced testing to patients and their families. Originally founded by scientists from the National Institutes of Health, GeneDx offers a world-renowned clinical genomics program with particular expertise in rare and ultra-rare genetic disorders. In addition to its market-leading exome sequencing service, GeneDx provides a comprehensive suite of additional genetic testing services.
In April 2022, GeneDx was acquired by Sema4, a patient-centered health intelligence company. The combined company is focused on accelerating the use of genomics and leveraging large-scale clinical data to enhance the standard of care through extensive precision medicine solutions.